Article info
Original article
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma
- Correspondence to Professor Dr Alexandar Tzankov, Institute of Pathology, University Hospital Basel, Schoenbeinstrasse 40, Basel CH-4031, Switzerland; atzankov{at}uhbs.ch and Dr Ken H Young, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Houston, TX 77030-4009, USA; khyoung{at}mdanderson.org
Citation
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma
Publication history
- Received March 13, 2013
- Revised May 7, 2013
- Accepted May 23, 2013
- First published June 17, 2013.
Online issue publication
October 31, 2013
Article Versions
- Previous version (17 June 2013).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions